Last edition
News about "I-Mab "
Everest Medicines to Invest USD 30.9 Million in I-MAB
Everest Medicines has announced a strategic equity investment of USD 30.9 million in US-based biotech firm I-Mab, strengthening its position in next-generation oncology and enhancing synergies across global markets.
I-Mab | 04/08/2025 | By Mrinmoy Dey
I-Mab partners with MorphoSys
Announces new license agreements for Felzartamab and TJ210
I-Mab | 16/06/2022 | By Sudeep Soparkar | 723
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy